Corient Private Wealth
GSK icon

Corient Private Wealth’s GSK GSK Stock Holding History

Corient Private Wealth’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.71M Sell
104,513
-120,918
-54% -$6.55M 0.01% 806
2025
Q4 		$10.8M Buy
225,431
+102,172
+83% +$4.77M 0.01% 750
2025
Q3 		$5.32M Buy
123,259
+31,273
+34% +$1.22M 0.01% 691
2025
Q2 		$3.53M Sell
91,986
-4,025
-4% -$154K ﹤0.01% 813
2025
Q1 		$3.72M Sell
96,011
-333
-0.3% -$12.2K 0.01% 767
2024
Q4 		$3.26M Buy
96,344
+10,895
+13% +$392K 0.01% 828
2024
Q3 		$3.49M Buy
85,449
+6,395
+8% +$262K 0.01% 866
2024
Q2 		$3.04M Buy
79,054
+4,926
+7% +$207K 0.01% 864
2024
Q1 		$3.18M Buy
74,128
+6,564
+10% +$271K 0.01% 835
2023
Q4 		$2.5M Sell
67,564
-1,014
-1% -$36.4K ﹤0.01% 905
2023
Q3 		$2.49M Sell
68,578
-129
-0.2% -$4.58K 0.01% 838
2023
Q2 		$2.45M Buy
68,707
+6,922
+11% +$248K 0.01% 836
2023
Q1 		$2.2M Buy
61,785
+29,016
+89% +$1.02M 0.01% 813
2022
Q4 		$1.16M Buy
+32,769
New +$1.09M ﹤0.01% 867

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Corient Private Wealth's GSK Position: Q1 2026 in Review

Corient Private Wealth reduced its GSK (GSK) stake by 54% in Q1 2026, selling an estimated $6.55M and leaving 104,513 shares worth $5.71M. The position accounts for 0.01% of the portfolio, ranked #806.

Corient Private Wealth first reported a position in GSK in Q4 2022 and has held it in 14 quarters since. The position peaked at $10.8M in Q4 2025. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Corient Private Wealth held 104,513 shares of GSK worth $5.71M as of Q1 2026.
  • Corient Private Wealth sold 120,918 GSK shares in Q1 2026, an estimated $6.55M.
  • GSK made up 0.01% of Corient Private Wealth's portfolio in Q1 2026, its #806 holding.
  • Corient Private Wealth first reported a position in GSK in Q4 2022 and has held it in 14 quarters since.
  • Corient Private Wealth's GSK position peaked at $10.8M in Q4 2025.
  • 1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.